The FDA assessed the protection and success of atidarsagene autotemcel determined by facts from 37 small children who received atidarsagene autotemcel in two one-arm, open up-label medical trials As well as in an expanded entry method.[seven] Small children who acquired treatment with atidarsagene autotemcel had been in comparison with untreated ch